Toll Free: 1-888-928-9744

Salivary Gland Cancer - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Salivary Gland Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Salivary Gland Cancer - Pipeline Review, H2 2016, provides an overview of the Salivary Gland Cancer (Oncology) pipeline landscape.

Salivary gland cancer is a rare form of cancer that begins in the salivary glands. Salivary gland cancer can begin in any of the salivary glands in mouth, neck or throat. Symptoms include a lump or swelling on or near jaw or in neck or mouth, numbness in part of face, difficulty swallowing and trouble opening mouth widely. Risk factors include age and radiation exposure. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Salivary Gland Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Salivary Gland Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Salivary Gland Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Salivary Gland Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.Salivary Gland Cancer.

Salivary Gland Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Salivary Gland Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Salivary Gland Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Salivary Gland Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Salivary Gland Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Salivary Gland Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Salivary Gland Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Salivary Gland Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Salivary Gland Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Salivary Gland Cancer - Overview 7 Pipeline Products for Salivary Gland Cancer - Comparative Analysis 8 Salivary Gland Cancer - Therapeutics under Development by Companies 9 Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes 10 Salivary Gland Cancer - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Salivary Gland Cancer - Products under Development by Companies 13 Salivary Gland Cancer - Products under Investigation by Universities/Institutes 14 Salivary Gland Cancer - Companies Involved in Therapeutics Development 15 Bayer AG 15 Ignyta, Inc. 16 Johnson & Johnson 17 Loxo Oncology, Inc. 18 Merck & Co., Inc. 19 Plexxikon Inc. 20 Taiwan Liposome Company, Ltd. 21 Salivary Gland Cancer - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 Cellular Immunotherapy for Oncology - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 entrectinib - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 LOXO-101 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 pembrolizumab - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 pexidartinib - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 regorafenib - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 tipifarnib - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 TLC-388 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Vaccine to Target WT1 for Oncology - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 Salivary Gland Cancer - Dormant Projects 101 Salivary Gland Cancer - Discontinued Products 102 Appendix 103 Methodology 103 Coverage 103 Secondary Research 103 Primary Research 103 Expert Panel Validation 103 Contact Us 103 Disclaimer 104
List of Tables
Number of Products under Development for Salivary Gland Cancer, H2 2016 7 Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Salivary Gland Cancer - Pipeline by Bayer AG, H2 2016 15 Salivary Gland Cancer - Pipeline by Ignyta, Inc., H2 2016 16 Salivary Gland Cancer - Pipeline by Johnson & Johnson, H2 2016 17 Salivary Gland Cancer - Pipeline by Loxo Oncology, Inc., H2 2016 18 Salivary Gland Cancer - Pipeline by Merck & Co., Inc., H2 2016 19 Salivary Gland Cancer - Pipeline by Plexxikon Inc., H2 2016 20 Salivary Gland Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 21 Assessment by Monotherapy Products, H2 2016 22 Number of Products by Stage and Target, H2 2016 24 Number of Products by Stage and Mechanism of Action, H2 2016 26 Number of Products by Stage and Route of Administration, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 30 Salivary Gland Cancer - Dormant Projects, H2 2016 101 Salivary Gland Cancer - Discontinued Products, H2 2016 102



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify